Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 23Andme Holding Co. (NQ: ME ) 4.700 +0.050 (+1.08%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about 23Andme Holding Co. < Previous 1 2 3 Next > 23andMe Regains Compliance With Nasdaq Listing Requirements October 30, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Appoints Three New Independent Directors to Board October 29, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South October 17, 2024 The new African American Genetic Groups feature traces customers' ancestral connections from before the early-to-mid-20th century migrations to more than 200 communities in Southern states From 23andMe, Inc. Via GlobeNewswire 23andMe Announces Completion of 1-for-20 Reverse Stock Split October 16, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Announces 1-for-20 Reverse Stock Split October 11, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Announces Mathew Knowles as New Brand Ambassador October 08, 2024 Collaboration to help increase awareness of the power of genetic testing when it comes to learning about personal health risks From 23andMe, Inc. Via GlobeNewswire 23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating September 25, 2024 Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics From 23andMe, Inc. Via GlobeNewswire Independent Directors of 23andMe Resign from Board September 17, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial September 15, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study September 15, 2024 From 23andMe, Inc. Via GlobeNewswire One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations September 12, 2024 23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population From 23andMe, Inc. Via GlobeNewswire 23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024 September 03, 2024 From 23andMe, Inc. Via GlobeNewswire Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program August 28, 2024 In conjunction with this new offering, 23andMe, Lemonaid Health’s parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s From 23andMe, Inc. Via GlobeNewswire 23andMe Reports First Quarter Fiscal 2025 Financial Results August 08, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Special Committee responds to CEO’s take-private proposal August 02, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Announces CEO’s Take-Private Proposal August 01, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe to Report Q1 FY2025 Financial Results July 25, 2024 From 23andMe, Inc. Via GlobeNewswire Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research July 25, 2024 Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer From 23andMe, Inc. Via GlobeNewswire 23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME July 19, 2024 From Kahn Swick & Foti, LLC Via Business Wire 23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel June 28, 2024 From 23andMe, Inc. Via GlobeNewswire 23andMe Launches New Genetic Report on Bipolar Disorder June 05, 2024 Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variants From 23andMe, Inc. Via GlobeNewswire 23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community June 04, 2024 Study aims to fill research gap and empower people through access to information about their health From 23andMe, Inc. Via GlobeNewswire 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting June 03, 2024 From 23andMe, Inc. Via GlobeNewswire Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history May 29, 2024 Findings from 23andMe research on Parkinson’s disease published in Brain From 23andMe, Inc. Via GlobeNewswire 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results May 23, 2024 From 23andMe, Inc. Via GlobeNewswire Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals May 14, 2024 Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity From 23andMe, Inc. Via GlobeNewswire 23andMe to Report Q4 and Full Year FY2024 Financial Results May 09, 2024 From 23andMe, Inc. Via GlobeNewswire Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case April 30, 2024 From Potter Handy LLP Via Business Wire 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented From 23andMe, Inc. Via GlobeNewswire 23andMe announces CEO’s intention to pursue a potential take-private April 18, 2024 From 23andMe, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
